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body,	giving	rise	 to	many	different	 tissue	types	such	as	bones	and	cartilage	of	 the	 face,	smooth	muscles,	
neurons	 and	 melanocytes.	 While	 studied	 extensively	 in	 animal	 models,	 neural	 crest	 development	 and	
disease	 have	 been	 poorly	 described	 in	 human	 due	 to	 the	 challenges	 in	 accessing	 embryonic	 tissues.	 In	
recent	 years,	 patient-derived	 human	 induced	 pluripotent	 stem	 cells	 (hiPSCs)	 have	 become	 easier	 to	
generate,	 and	 several	 streamlined	 protocols	 have	 enabled	 robust	 differentiation	 of	 hiPSCs	 to	 the	 neural	
crest	lineage.	Thus,	a	unique	opportunity	is	offered	for	modelling	neurocristopathies	using	patient	specific	




Here,	we	establish	a	pipeline	 for	profiling	hiPSCs	during	differentiation	 toward	 the	neural	 crest	 stem	cell	
fate.	 This	 can	 be	 used	 to	 characterise	 the	 differentiation	 properties	 of	 the	 neural	 crest-like	 cells.	 Two	
	 2	
different	 BBS10	mutant	 lines	 showed	 a	 reduction	 in	 expression	 of	 the	 characteristic	 neural	 crest	 gene	
expression	profile.	 Further	 analysis	 of	 both	BBS10	mutant	 lines	 highlighted	 the	 inability	 of	 these	mutant	
lines	 to	differentiate	 towards	a	neural	 crest	 fate,	which	was	also	 characterised	by	a	decreased	WNT	and	
BMP	 response.	Altogether,	 our	 study	 suggests	 a	 requirement	 for	wild-type	BBS10	 in	human	neural	 crest	
development.	 In	 the	 long	 term,	approaches	 such	as	 the	one	we	describe	will	 allow	direct	 comparison	of	





Neural	 crest	 cells	 are	 a	 highly	migratory,	multipotent	 stem	 cell	 population	 that	 contributes	 to	 a	
broad	 range	 of	 tissues,	 including	 craniofacial	 bone	 and	 cartilage,	 peripheral	 neurons,	 glia,	 pigment,	 and	
other	 cells	 during	 embryonic	 development	 (Trainor,	 2014).	 Elucidating	 the	 cellular	 and	 molecular	
mechanisms	of	lineage	specification	and	migration	of	neural	crest	stem	cells	is	essential	for	understanding	
the	pathogenesis	of	neurocristopathies,	a	 family	of	diseases	caused	by	anomalies	 in	 the	migration	or	cell	
behaviour	of	neural	 crest	 cells.	 Ciliopathies	 are	a	 class	of	 genetic	disorders	 characterised	by	mutation	of	
proteins	 affecting	 the	 structure	 or	 function	 of	 the	 cilium	 (Eggenschwiler	 &	 Anderson	 2007;	 Ishikawa	 &	
Marshall	 2011).	 The	 cilium	 is	 a	 microtubule-based	 cellular	 organelle	 crucial	 for	 cell	 signalling,	







proteins	 forming	 the	 BBSome	 (Figure	 1A).	 The	 BBSome	 is	 an	 adaptor	 complex	 that	 is	 crucial	 for	 cilia	
function	(Suspitsin	&	Imyanitov	2016;	Jin	&	Nachury,	2009).	Clinical	findings	indicate	that	patients	carrying	
BBS	mutations	often	present	with	 subclinical	 craniofacial	 changes	 including	 speech	and	oral	phenotypes,	
mid-facial	 flattening	and	some	mild	retrognathia	(Panny	et	al.	2017;	Tobin	et	al.	2008).	 	 In	addition,	Bbs6	
mutant	mouse	skulls	showed	a	reduction	in	the	size	of	the	pre-maxillary	and	maxillary	regions	(Tobin	et	al.	






2010;	 Zhang	 et	 al.	 2012;	 Billingsley	 et	 al.	 2010;	 Stoetzel	 et	 al.	 2007;	 Stoetzel	 et	 al.	 2006).	 Phenotypes	
associated	with	BBS6,	10	and	12	are	thought	to	be	more	severe	than	other	commonly	mutated	BBS	genes	
like	BBS1	 (Castro-Sánchez	 et	 al.	 2015).	 Furthermore,	bbs10	morphant	 zebrafish	 larvae	 exhibit	 shortened	
body	axis	and	poor	somitic	definition	among	other	more	variable	phenotypes,	while	a	sub-phenotypic	dose	
of	bbs10	morpholino	oligonucleotides	(MO)	exacerbates	the	phenotypes	observed	in	other	bbs	morphants	




knockdowns	 also	 fit	 generally	 with	 observations	 linking	 ciliopathic	 mutations	 and	 craniofacial	
malformations	 in	 humans.	 It	 is	 unclear	what	 specific	 alterations	 in	 neural	 crest	 cell	 (NCC)	 functions	 (e.g	
differentiation,	 migration)	 are	 caused	 by	 mutations	 in	 BBS10.	 To	 define	 the	 pathogenic	 mechanisms	 of	
these	mutations,	we	sought	to	model	NCC	induction	in	BBS10	mutant	iPSCs.		
Human	 induced	 pluripotent	 stem	 cells	 (hiPSC)	 are	 a	 powerful	 tool	 for	 the	 study	 of	 human	
developmental	 disorders	 as	 they	 can	 be	 used	 to	 model	 genotype-specific	 molecular	 and	 cellular	
phenotypes	during	differentiation.	Over	the	last	decade,	several	protocols	have	been	developed	for	neural	
crest	cell	(NCC)	induction	from	hiPSCs,	using	defined	factors	at	specific	time	points	to	generate	‘purer’	cell	
populations	 which	 can	 be	 used	 to	 study	 induction,	 migration	 and	 differentiation	 (Leung	 et	 al.	 2016;	
Menendez	et	al.	2013;	Chambers	et	al.	2013;	reviewed	in	Zhu	et	al.,	2016).	The	Human	Induced	Pluripotent	
Stem	Cell	Initiative	(HipSci,	http://www.hipsci.org)	has	generated	and	characterised	a	panel	of	hundreds	of	
hiPSCs	 including	 from	 a	 significant	 cohort	 of	 Bardet-Biedl	 Syndrome	 (BBS)	 patients	 hosting	 a	 diverse	
spectrum	of	mutations	in	genes	involved	in	BBS.	Here,	as	a	proof	of	concept,	we	use	the	recently	described	
Leung	et	al.,	protocol	to	obtain	efficient	neural	crest	induction	and	compare	HipSci	cell	lines	from	healthy	
volunteers	 with	 two	 cell	 lines	 obtained	 from	 Bardet-Biedl	 Syndrome	 patients	 carrying	 BBS10	mutations	
(Table	1).	We	show	that	both	mutant	BBS	hiPSCs	have	altered	neural	crest	 induction	and	differentiation,	









Table	 1).	 hiPSCs	 were	 maintained	 in	 Essential	 8	 media	 (ThermoFisher)	 on	 an	 extracellular	 matrix	
replacement,	Matrigel	(Corning).	XIRY	was	initially	obtained	cultured	on	Matrigel	whereas	QOLG	and	LAIG,	
acquired	on	vitronectin,	were	cultured	on	Matrigel	 for	 several	passages	 to	ensure	 that	 all	 cell	 lines	were	
comparable.	 Cells	 were	 typically	 passaged	 twice	 weekly	 using	 0.5mM	 EDTA,	 dissociated	 with	 gentle	
pipetting	and	analysed	between	passages	30-60.		
TABLE	1	
Donor	 Cell	line	 BBS10	variant	1	 BBS10	variant	2	 Age	 Sex	 Ethnicity	
QOLG	 Qolg_1	 Wildtype	 Wildtype	 35-39	 Male	 White,	British	
KEGD	 Kegd_2	 Wildtype	 Wildtype	 40-44	 Male	 White,	British	
XIRY	 Xiry_5	 c.989T>C/p.Val330Ala	 c.235dup/p.Thr79Asnfs*17	 35-39	 Male	 White,	British	
LAIG	 Laig_1	 c.285A>T/p.Arg95Ser	 c.2119_2120del/p.Val707*	 25-29	 Female	 White,	European	
	
Neural	crest	induction:		
Neural	 crest	 induction	 was	 carried	 out	 as	 per	 Leung	 et	 al.	 2016	 (Leung	 et	 al.	 2016),	 which	 is	
designed	to	mimic	normal	neural	crest	development	(Figure	2).	TrypLE	Express	(Thermo	Fisher)	was	used	to	
detach	hiPSCs	into	a	single	cell	suspension.	Next,	200,000	hiPSCs	were	plated	in	each	well	of	a	6-well	plate	
coated	with	Matrigel.	At	 the	 start	 of	 the	 induction	protocol	 (time	=	0	hours),	wells	were	 incubated	with	
neural	 crest	 induction	medium	 +	 10µM	 Y-27632	 (Cell	 Guidance	 Systems)	 for	 the	 first	 48	 hours	 (48h)	 of	
culture,	then	in	neural	crest	induction	media	alone	for	the	 indicated	time.	Samples	were	then	fixed	in	4%	
PFA	in	PBS	for	antibody	staining	or	lysed	in	Trizol	(Sigma)	for	RNA	extraction.	Neural	crest	induction	media	








were	 incubated	 at	 room	 temperature	 for	 1-2	 hours.	Next,	 three	 15	minute	washes	 in	 PBS	with	 1%	BSA,	




Antibody	 Targets:	 Concentration	 Supplier	(catalog	number)	
ARL13B	 Ciliary	axoneme	 1:500	 Proteintech	(17711-1-AP)	
SOX10	 migratory	neural	crest	 1:500	 Santa	Cruz	(sc-365692)	




Anti-mouse	488	 secondary	antibody	 1:500	 Invitrogen	(A11001)	
Anti-rabbit	568	 secondary	antibody	 1:500	 Invitrogen	(A11011)	
Anti-rabbit	488	 secondary	antibody	 1:500	 Invitrogen	(A11008)	
	
Microscopy	and	Imaging:		












as	 per	manufacturer’s	 instructions.	 RNA	was	 then	DNAse	 I	 (Promega)	 treated.	 500	 ng	 to	 1	µg	 of	DNAse	




























We	 selected	 several	 lines	 from	 the	HipSci	 cell	 bank:	 a	 control	 line,	 KEGD	 (cilia	 quantitation)	 and	
QOLG	(used	for	the	majority	of	our	assays)	and	two	BBS10	mutant	lines,	XIRY	and	LAIG.	Both	mutant	lines	




lacking	 the	 final	16	amino	acids	 (V707*)	 (Figure	1B).	Based	on	 these	genotypes,	we	expect	 that	 the	XIRY	
variants	 will	 have	 a	 more	 significant	 impact	 on	 protein	 function.	Matrigel	 was	 used	 to	 wean	 lines	 for	
comparable	results	and	all	cell	lines	exhibited	an	embryonic	stem	(ES)	cell-like	state,	forming	tight	colonies	
of	packed	cells	 (Figure	1C-E).	Cultures	were	discarded	 if	delaminating,	 if	differentiated	cells	were	present	
on	 greater	 than	 25%	 of	 the	 colonies,	 or	 if	 large	 regions	 of	 non-colony	 bound	 cells	 were	 present.	 We	
confirmed	 that	our	 culture	 conditions	were	 suitable	 for	maintaining	pluripotency	 in	all	 three	hiPSC	 lines.	
Immunostaining	for	OCT3/4,	one	of	the	defining	features	of	pluripotency,	was	carried	out	on	all	three	lines	







To	confirm	that	BBS10	mutant	cells	are	still	able	 to	generate	cilia,	we	performed	 immunostaining	on	 the	
hiPSCs	 with	 ARL13B,	 a	 marker	 of	 the	 ciliary	 axoneme.	 We	 found	 that	 both	 control	 lines	 expressed	 an	
abundance	of	cilia-specific	ARL13B	staining	(KEGD,	shown	in	Figure	1F;	QOLG,	data	not	shown).	Both	BBS10	
mutant	 lines	 also	 had	 cells	 with	 positive	 staining	 (Figure	 1G-H).	 Both	 mutant	 lines	 expressed	 cilia;	






To	 confirm	 that	 both	normal	 and	BBS10	mutant	 hiPSCs	 could	be	differentiated	 towards	 the	neural	 crest	
lineage,	 we	 used	 a	 5-day	 induction	 protocol	 where	 activation	 of	 the	 WNT	 pathway	 (via	 inhibition	 of	






at	 96	 hours	 of	 culture	 (Figure	 3J,	 3N,	 blue	 arrowheads).	 These	 results	 suggest	 a	 delay	 in	 neural	 crest	
induction	in	BBS10	mutants. 
Furthermore,	despite	being	 initially	plated	at	 the	 same	density,	 fewer	cells	were	observed	 in	 the	




























Specifically,	we	 tested	 the	control	 line	QOLG	and	 the	mutant	 line	XIRY,	as	 these	 lines	were	derived	 from	
age/gender	matched	donors.		
	 To	 confirm	 the	 exit	 from	 pluripotency,	 we	 first	 analysed	 the	 expression	 of	 CMYC,	 NANOG	 and	




the	 iPSC	 period	 but	 not	 NANOG	 or	 CMYC	 (Figure	 6C).	 By	 120h	 of	 culture,	 both	 lines	 had	 almost	 no	
expression	 of	 pluripotency	 markers.	 Nevertheless,	 the	 delayed	 loss	 of	 pluripotency	 markers	 could	 be	
indicative	of	a	failure	to	respond	to	signals	that	induce	the	neural	plate	border.	
	 We	 then	 examined	 expression	 of	 neural	 plate	 border	 markers,	 including	 PAX3,	 PAX7,	 TFAP2A	
(Figure	 6D-F).	As	expected,	 the	 control	 line	 showed	an	 increase	 in	 all	 three	neural	 plate	border	markers	
over	time,	with	steadily	increasing	levels	at	48h	and	120h.	In	contrast,	while	there	was	some	increase	in	all	
three	markers	at	48h	 in	XIRY	compared	to	the	start	of	the	 induction,	neither	PAX3	nor	PAX7	 reached	the	








during	 the	 differentiation	 protocol,	 expression	 levels	 in	 both	 mutant	 cell	 lines	 were	 significantly	 lower	
compared	 to	control	 (Figure	6G-I).	 It	 is	worth	noting	 that	prior	 to	neural	 crest	 induction,	 LAIG	expressed	
significantly	higher	 levels	of	FOXD3	 (Figure	6G),	which	was	 lost	by	48	hours	of	 induction.	 This	 raised	 the	
possibility	that	the	mutant	cell	lines	responded	to	the	differentiation	protocol	via	induction	of	a	non-neural	
crest	state.	Note	that	we	see	some	moderate	induction	of	neural	border	and	neural	crest	markers	in	XIRY.	
Surprisingly,	we	 found	 that	 XIRY	 expressed	 significantly	 higher	 levels	 of	 the	mesodermal	marker	
Brachyury	(BRY)	by	2	days	of	culture	(Figure	7A).	SOX2	expression	is	an	early	marker	of	pluripotency	(during	
the	 hiPSC	 stage)	 and	 then	 becomes	 a	marker	 of	 neural	 tissues.	 Consistent	with	 this,	 control	 QOLG	 cells	
express	SOX2	initially	(0	hrs),	followed	by	a	peak	at	neural	border	stages	(48	hours)	and	a	dip	as	neural	crest	
induction	 progresses.	 In	 contrast,	 we	 found	 that	 XIRY	 cells	 had	 normal	 levels	 of	 SOX2	 initially,	 but	 this	
decreased	significantly	by	day	5	of	culture	(Figure	7B).	SOX2	expression	in	the	mutant	LAIG	was	significantly	
lower	during	pluripotency	stages,	but	responded	normally	to	induction.		
We	 next	 examined	 two	markers	 of	 the	 pre-placodal	 ectoderm	 (PPE).	 Similar	 to	 the	 neural	 crest	




culture	 (Figure	 7C).	 At	 all	 stages	 throughout	 induction,	 expression	 of	 ZIC1	was	 significantly	 reduced	 in	
mutant	LAIG.	Sustained	ZIC1	expression	is	necessary	for	activation	of	pre-placodal	ectoderm	genes	such	as	





line	 had	 a	 dampened	 response	 to	 these	 key	 signals.	 To	 test	 this,	 we	 examined	 expression	 of	 the	Wnt-
responsive	 gene	Axin2	 and	 the	BMP-responsive	 gene	MSX1	 (Figure	 7E,	 7F,	 respectively).	 Consistent	with	




(Figure	7F).	Due	 to	 the	 crucial	 role	 for	 cilia	 in	Hedgehog	 (Hh)	 signalling,	we	also	examined	 the	Hh	 target	
Patched1	(PTC1).	There	was	generally	no	significant	difference	between	control	and	mutant	lines;	however,	
mutants	did	show	some	variable	increase	early	in	induction	(Figure	7G).	This	could	indicate	a	lack	of	ciliary-








multiple	organ	systems	makes	 it	particularly	difficult	 to	assess	 function	of	this	 lineage	 in	vitro.	Therefore,	
recent	 advances	 in	 human-derived	 cellular	 approaches	 offer	 new	 tools	 for	 the	 study	 of	 complex	 human	
conditions.	 To	 be	 able	 to	 best	 use	 these	 patient-derived	 cells,	 there	 is	 an	 acute	 need	 to	 establish	
streamlined,	 robust	and	reproducible	assays	to	test	each	step	of	neural	crest	 formation.	 In	 this	work,	we	
used	 the	 short	 neural	 crest	 induction	 protocol	 developed	 by	 Leung	 and	 colleagues	 to	 determine	 key	
requirements	for	a	disease	gene	in	neural	crest	stem	cell	pathology	(Leung	et	al.,	2016).		
The	 long-term	goal	of	 a	project	 such	as	 this	 is	 the	ability	 to	model	 “disease	 in	a	dish”,	using	 the	
patient’s	own	cells	 to	understand	 the	underlying	cellular	and	molecular	causes	of	pathology	or	using	 the	
patient’s	cells	to	design	new	therapeutics.	This	approach	complements	existing	animal	models,	which	are	
very	powerful	for	in	vivo	studies,	but	often	do	not	entirely	recapitulate	the	human	condition.	For	example,	
genetic	 knock-outs	 of	 crucial	 genes	 frequently	 lead	 to	 embryonic	 lethality.	 However,	 it	 is	 clear	 from	
disorders	such	as	BBS,	that	the	human	disease	variants	are	often	of	unknown	function	and	difficult	to	study	
without	 a	 clear	 cellular	 or	molecular	 assay.	 Furthermore,	 genes	 such	 as	BBS10	 lead	 to	 a	 broad	 range	 of	
phenotypes	 in	 patients,	 including	 different	 manifestations	 from	 sibling	 to	 sibling	 (carrying	 the	 same	
variant).	This	variability	also	complicates	our	understanding	of	gene-function	interactions.	
To	truly	link	gene	identity	to	gene	function	using	animal	models,	it	would	be	necessary	to	generate	





Although	 this	 study	 is	only	 focused	on	 two	BBS10	mutant	 lines,	our	work	clearly	 illustrates	 the	power	of	
defined	protocols	to	link	gene	variation	to	gene	function.		
BBS10	 is	 a	 ciliopathy	 gene,	 and	 is	 one	 of	 the	 most	 common	 genes	 mutated	 in	 Bardet	 Biedl	
Syndrome.	 Despite	 our	 knowledge	 of	 multiple	 BBS	 human	 disease	 variants,	 it	 has	 been	 difficult	 to	
understand	 the	 direct	 causative	 mechanisms	 underlying	 the	 human	 condition.	 An	 established	





specific	mutations	 for	gain-	or	 loss-of-function	during	neural	crest	 induction.	This	will	allow	us	 to	directly	
compare	 the	 effect	 of	 different	 variants	 on	 the	 same	 genetic	 background	 in	 order	 to	 help	 us	 begin	 to	
understand	the	pleiotropic	effects	seen	in	humans.		
Applications	of	an	assay	such	as	 this	one	are	also	broad.	We	can	use	this	protocol	 to	understand	
both	 the	 cellular	 and	molecular	 profiles	 of	 patient	 specific	 cells.	 For	 example,	 when	 Leung	 et	 al.	 (2016)	
initially	developed	the	short-term	protocol,	they	tested	the	requirements	of	fibroblast	growth	factor	(FGF)	
and	bone	morphogenetic	protein	 (BMP)	 signalling	during	 the	 induction	phase.	They	noted	 that	excessive	
levels	 of	 FGF	 led	 to	 increased	mesodermal	 specification,	 while	 BMP4	 supplementation	 led	 to	 increased	
non-neural	ectoderm.	In	contrast,	BMP	inhibition	reduced	the	levels	of	SOX10	positive	neural	crest	cells.	As	
BBS10	 is	 a	 key	 ciliopathy	 gene,	 and	 the	 cilium	 can	 serve	 as	 a	 node	 for	 signal	 transduction,	 it	 was	
conceivable	 that	 the	 phenotypes	 seen	 in	 our	 BBS10	 hiPSCs	 were	 due	 to	 an	 inability	 to	 respond	 to	 the	
appropriate	 inductive	cues.	As	 the	main	driver	of	 the	neural	crest	 induction	protocol	 in	 this	assay	 is	Wnt	
activation	via	GSK3	 inhibition,	our	key	finding	here	suggests	that	the	ciliopathic	hiPSCs	have	a	diminished	
ability	 to	respond	to	 the	GSK3	 inhibitor	CHIR99021,	which	 is	 included	throughout	 the	 induction	protocol.	
Indeed,	 the	 XIRY	 line	 initially	 responded	 to	 CHIR99021	 by	 upregulating	 the	 Wnt	 target	 gene	 AXIN2	
modestly;	however,	further	treatment	did	not	recapitulate	the	upregulation	seen	in	QOLG	at	120h	(Figure	
7E).	XIRY	also	fails	to	activate	expression	of	the	BMP	target	gene	MSX1.	At	this	point,	it	is	unclear	whether	
XIRY	 is	 unable	 to	 respond,	 or	 whether	 there	 is	 another	 overriding	 signal.	 In	 the	 long-term,	 a	 thorough	
molecular	analysis	such	as	RNAseq	would	be	a	more	thorough	way	to	compare	responsiveness	of	wildtype	
and	 mutant	 cells.	 Nevertheless,	 our	 findings	 provide	 an	 intriguing	 starting	 point	 for	 understanding	 the	
inductive	cues	necessary	for	neural	crest	development.	




genes	 during	 establishment	 of	 the	 neural	 plate	 border	 and	 induction	of	 the	 neural	 crest	 lineage.	Having	
established	this	pipeline,	these	assays	can	be	optimised	to	probe	some	key	characteristics	of	neural	crest	
cells.	For	example,	two	of	the	defining	features	of	neural	crest	cells	are	the	prodigious	migratory	capacity	
and	 the	multipotency.	Endpoint	and	 live	high-content	 imaging	assays	 can	be	developed	using	 these	 read	
outs.	 As	 we	 can	 already	 see	 from	 our	 studies,	 BBS10	 mutant	 cells	 have	 very	 different	 morphology,	
protrusive	activity	and	migratory	capacity	(data	not	shown).	In	fact,	some	ciliopathies,	including	BBS,	have	
been	 associated	 with	 Hirschsprung’s	 disease,	 which	 is	 characterised	 by	 a	 failure	 of	 migration	 in	 neural	
crest-derived	 enteric	 neurons	 (de	 Pontual	 et	 al.,	 2009).	 We	 expect	 to	 be	 able	 to	 synchronise	 our	 cell	
populations	 to	 readily	 and	 directly	 compare	 the	 cellular	 behaviours	 (as	 in	 Wiseman	 et	 al,	 2019).	 With	




Overall,	 the	use	of	patient	derived	hiPSCs	 for	 the	modelling	of	neurocristopathic	phenotypes	can	
elucidate	 the	 requirement	 of	 specific	 genes	 at	 crucial	 points	 of	 neural	 crest	 development.	 This	 human	
genetic	 background	 specific	 approach	 in	 combination	 with	 animal	 models	 will	 lead	 to	 a	 greater	
understanding	of	mammalian	neural	crest	development	and	disease.	
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A)	 Schematic	 representation	 of	 the	 primary	 cilium.	 AX	 =	 axoneme,	 BB	 =	 basal	 body,	 IFT	 =	 intraflagellar	
transport.	 BBS1-20	 proteins	 are	 depicted	 in	 their	 associated	 complex	 (BBSome	 and	 chaperonin)	 or	 by	
localisation	 to	 other	 structures.	 B)	 Schematics	 showing	 BBS10	 transcript	 and	 protein	 structure	 (723AA).	
Regions	exhibiting	homology	with	chaperonin	domains	are	shown	in	the	wildtype	protein	(scheme	adapted	
from	 (Álvarez-Satta	 et	 al.	 2017)).	 Variants	 from	 two	 BBS10	 mutant	 lines	 XIRY	 (blue)	 and	 LAIG	 (red)	 are	
mapped	onto	protein	domains	with	comparison	to	control	(QOLG	or	KEGD).		
C-E)	 Cells	 were	 immunostained	 for	 the	 pluripotency	 marker	 OCT3/4.	 Control	 (QOLG)	 cells	 and	 BBS10	
mutants	 (XIRY	and	LAIG)	all	had	positive	staining	 in	 the	nucleus.	Merge	with	DNA	dye	Hoechst	 (C’-E’).	All	
cells	exhibit	staining	although	there	is	some	variability	with	less	intense	staining	being	seen	in	the	central	
regions	of	the	colonies.		



















Discrete	 iPSC-like	 colonies	 can	be	 seen	at	24h	 in	 all	 rows	 (B,	G	and	 L).	 In	 control	 cultures,	 cells	 are	 seen	
delaminating	 from	 colonies	 at	 48h	 (blue	 arrowhead,	 C);	 whereas	 mutant	 cultures	 start	 showing	
delamination	 at	 96h	 (blue	 arrowheads,	 I	 and	N).	 By	 120h	 there	 are	 still	 some	dense,	 colony-like	 regions	
present	in	all	cultures	(yellow	arrowheads,	E,	J	and	O.	Scale	bars	=	50µm.	
Figure	4.	Delaminated	neural	crest	cells	have	a	mesenchymal	morphology.		
Phase	 contrast	 images	 of	 differentiating	 hiPSCs	 cultures	 taken	 during	 neural	 crest	 induction	 at	 specified	
time	points.	 	Control	QOLG	(A-C),	mutant	XIRY	(D-F).	Note	that	control	QOLG	cells	at	48	hours	(A)	exhibit	









Neural	 crest	 induction	was	 carried	 out	 on	 control	 QOLG	 (blue),	mutant	 XIRY	 (purple)	 and	 LAIG	 (orange)	
hiPSC	 lines.	 Cells	 were	 harvested	 for	 RNA	 before	 plating	 (iPSC,	 time	 =	 0hrs),	 at	 48hrs	 and	 120hrs	 of	






Neural	 crest	 induction	was	 carried	 out	 on	 control	 QOLG	 (blue),	mutant	 XIRY	 (purple)	 and	 LAIG	 (orange)	
hiPSC	 lines.	 Cells	 were	 harvested	 for	 RNA	 before	 plating	 (iPSC,	 time	 =	 0hrs),	 at	 48hrs	 and	 120hrs	 of	
differentiation.		
A-D)	RT-qPCR	analysis	 for	 a	mesodermal	marker,	BRY	 (A),	 a	 neural	marker,	SOX2	 (B),	 neural	 border/pre-




BMP	signalling	 (F)	and	PTC1,	 a	 transcriptional	 target	of	Hedgehog	signalling	 (G).	 (E)	Note	 transient	 increase	 in	
AXIN2	expression	in	XIRY	from	0	hours	to	48	hours,	but	a	decrease	by	120	hours.	(F)	Note	a	failure	to	activate	
MSX1	expression	in	XIRY	and	LAIG	compared	to	control	QOLG.	(G)	Note	variability	of	PTC1	expression	in	XIRY	at	0	
hours	and	both	mutants	at	48	hours.P-values	were	determined	using	unpaired	Student’s	t-tests	(*	-	P=<0.05,	
**	-	P=<0.001,	***	-	P=<0.0001).		 	
	 16	
REFERENCES	
Adel	Al-lami	et	al.,	2016.	Micrognathia	in	mouse	models	of	ciliopathies.	Biochem	Soc	Trans.	(6),	p1753-
1759.		
Álvarez-Satta,	M.,	Castro-Sánchez,	S.	&	Valverde,	D.,	2017.	Bardet-Biedl	Syndrome	as	a	Chaperonopathy:	
Dissecting	the	Major	Role	of	Chaperonin-Like	BBS	Proteins	(BBS6-BBS10-BBS12).	Frontiers	in	molecular	
biosciences,	4(July),	p.55.	
Billingsley,	G.	et	al.,	2010.	Mutations	in	chaperonin-like	BBS	genes	are	a	major	contributor	to	disease	
development	in	a	multiethnic	Bardet-Biedl	syndrome	patient	population.	Journal	of	Medical	Genetics,	
47(7),	pp.453–463.	
Bolande,	R.P.,	1974.	The	neurocristopathies:	A	unifying	concept	of	disease	arising	in	neural	crest	
maldevelopment.	Human	Pathology,	5(4),	pp.409–429.	
Castro-Sánchez,	S.	et	al.,	2015.	Exploring	genotype-phenotype	relationships	in	Bardet-Biedl	syndrome	
families.	Journal	of	Medical	Genetics,	52(8),	pp.503–513.	
Chambers,	S.M.	et	al.,	2013.	Dual-SMAD	Inhibition/WNT	Activation-Based	Methods	to	Induce	Neural	Crest	
and	Derivatives	from	Human	Pluripotent	Stem	Cells.	In	Methods	in	Molecular	Biology.	pp.	329–343.	
Cognard,	N.	et	al.,	2015.	Comparing	the	Bbs10	complete	knockout	phenotype	with	a	specific	renal	epithelial	
knockout	one	highlights	the	link	between	renal	defects	and	systemic	inactivation	in	mice.	Cilia,	4(1),	
p.10.	
Cortés,	CR	et	al.,	2015.	Unmasking	the	ciliopathies:	craniofacial	defects	and	the	primary	cilium.	Wiley	
Interdiscip	Rev	Dev	Biol.	4(6),	p637-53.	
de	Pontual	L,	et	al.,	2009.	Epistasis	between	RET	and	BBS	mutations	modulates	enteric	innervation	and	
causes	syndromic	Hirschsprung	disease.	Proc	Natl	Acad	Sci	U	S	A.	106(33),	pp	13921-6.		
Eggenschwiler,	J.T.	&	Anderson,	K.	V,	2007.	Cilia	and	developmental	signaling.	Annual	review	of	cell	and	
developmental	biology,	23,	pp.345–373.	
Forsythe,	E.	&	Beales,	P.L.,	2012.	Bardet–Biedl	syndrome.	European	Journal	of	Human	Genetics,	pp.8–13.	
Hong,	C.-S.	&	Saint-Jeannet,	J.-P.,	2007.	The	Activity	of	Pax3	and	Zic1	Regulates	Three	Distinct	Cell	Fates	at	
the	Neural	Plate	Border	M.	Bronner-Fraser,	ed.	Molecular	Biology	of	the	Cell,	18(6),	pp.2192–2202.	
Ishikawa,	H.	&	Marshall,	W.F.,	2011.	Ciliogenesis:	building	the	cell’s	antenna.	Nature	reviews.	Molecular	cell	
biology,	12(4),	pp.222–234.	
	 17	
Jin,	H	&	Nachury,	MV.	2009.	The	BBSome.	Current	Biology,	19(12),	ppR472-3.		
Leung,	A.W.	et	al.,	2016.	WNT/b-catenin	signaling	mediates	human	neural	crest	induction	via	a	pre-neural	
border	intermediate.	Development,	143(3),	pp.398–410.	
Menendez,	L.	et	al.,	2013.	Directed	differentiation	of	human	pluripotent	cells	to	neural	crest	stem	cells.	
Nature	Protocols,	8(1),	pp.203–212.	
Nathwani,	B.B.	et	al.,	2014.	Morphological	differences	of	primary	cilia	between	human	induced	pluripotent	
stem	cells	and	their	parental	somatic	cells.	Stem	cells	and	development,	23(2),	pp.115–23.	
Okuno,	H.	et	al.,	2017.	CHARGE	syndrome	modeling	using	patient-iPSCs	reveals	defective	migration	of	
neural	crest	cells	harboring	CHD7	mutations.	eLife,	6,	pp.1–26.	
Panny,	A.	et	al.,	2017.	Oral	and	Craniofacial	Anomalies	of	Bardet-Biedl	Syndrome:	Dental	Management	in	
the	Context	of	a	Rare	Disease.	Journal	of	Dental	Research,	p.002203451771691.	
Seo,	S.	et	al.,	2010.	BBS6,	BBS10,	and	BBS12	form	a	complex	with	CCT/TRiC	family	chaperonins	and	mediate	
BBSome	assembly.	Proceedings	of	the	National	Academy	of	Sciences	of	the	United	States	of	America,	
107(4),	pp.1488–93.	
Schock	EN,	et	al.,	2015.	Using	the	avian	mutant	talpid2	as	a	disease	model	for	understanding	the	oral-facial	
phenotypes	of	oral-facial-digital	syndrome.	Dis	Model	Mech.	8(8)	p.	855-66.	
Stoetzel,	C.	et	al.,	2006.	BBS10	encodes	a	vertebrate-specific	chaperonin-like	protein	and	is	a	major	BBS	
locus.	Nature	Genetics,	38(5),	pp.521–524.	
Stoetzel,	C.	et	al.,	2007.	Identification	of	a	Novel	BBS	Gene	(BBS12)	Highlights	the	Major	Role	of	a	
Vertebrate-Specific	Branch	of	Chaperonin-Related	Proteins	in	Bardet-Biedl	Syndrome.	The	American	
Journal	of	Human	Genetics,	80(1),	pp.1–11.	
Suspitsin,	E.N.	&	Imyanitov,	E.N.,	2016.	Bardet-Biedl	Syndrome.	Molecular	Syndromology,	7(2),	pp.62–71.	
Tobin,	J.L.	et	al.,	2008.	Inhibition	of	neural	crest	migration	underlies	craniofacial	dysmorphology	and	
Hirschsprung’s	disease	in	Bardet-Biedl	syndrome.	Proceedings	of	the	National	Academy	of	Sciences	of	
the	United	States	of	America,	105(18),	pp.6714–6719.	
Trainor,	P	(editor)	2014.	Neural	crest	cells	:	evolution,	development,	and	disease.	Academic	Press.	ISBN	
0124017304.	
Vega-Lopez,	G.A.	et	al.,	2018.	Neurocristopathies:	New	insights	150	years	after	the	neural	crest	discovery.	
Developmental	Biology,	(November	2017),	pp.1–34.	
	 18	
Wiseman,	E.	et	al.,	2019	Integrated	Multiparametric	High-Content	Profiling	of	Endothelial	Cells.	SLAS	
Discovery,	SLAS	Discovery	(March	2019),	pp.	254-273.	
Zhang,	Q.	et	al.,	2012.	BBS	proteins	interact	genetically	with	the	IFT	pathway	to	influence	SHH-related	
phenotypes.	Human	Molecular	Genetics,	21(9),	pp.1945–1953.	
	







